LCTX - AMEX
Lineage Cell Therapeutics, Inc.
$1.21
-0.83%Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
At a Glance
Live SnapshotLineage Cell Therapeutics, Inc. Management Team
Dr. Rami Skaliter Ph.D.
Chief Executive Officer of Cell Cure Neurosciences
Mr. Brian M. Culley M.A., M.B.A.
Chief Executive Officer, President & Director
Compensation
$1,031,550
Ms. Jill Ann Howe
Chief Financial Officer & Principal Financial and Accounting Officer
Compensation
$599,950
Ms. Brandi L. Roberts CPA, M.B.A.
Consultant
Compensation
$407,450
Ms. Ioana C. Hone
Director of Investor Relations
Mr. George A. Samuel III, J.D.
General Counsel & Company Secretary
Compensation
$599,450
Ms. Alexandra Hernandez
Senior Director of Finance & Controller
Dr. Charlotte Hubbert Ph.D.
Vice President of Corporate Development
Dr. Harold D. Waitz
Vice President of Regulatory Affairs & Quality Control
Compensation
$90,000
Lineage Cell Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $24K worth of LCTX shares, with no selling activity reported.
3 Months
15.0K
24.38K
0
0.00
+24K
+$24K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Culley Brian M
Director, Officer: President And Ceo
$24K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $24K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
LCTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 26, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 09, 2024 | December 09, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | July 27, 2023 | July 27, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | April 29, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | August 03, 2021 | August 03, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 07, 2020 | August 07, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 14, 2019 | June 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 29, 2018 | March 29, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.